Company: AEMD
Filing Date: 2025-04-08
Form Type: PRE 14A
Source: 0001683168-25-002332
Chunk: 30

Company: AETHLON MEDICAL INC
Filing Date: 2025-04-08
Form: PRE 14A
Chunk 30
---
 comply with the Nasdaq minimum bid price requirement and if deemed to be in the interest of the Company.

<div align='center'>OUR BOARD OF DIRECTORS UNANIMOUSLY RECOMMENDS A VOTE “FOR” THE APPROVAL OF A REVERSE STOCK SPLIT AS SET FORTH IN PROPOSAL 1.</div>

| 16 |

<div align='center'>PROPOSAL NO. 2 - To approve the issuance of shares of common stock upon exercise of Inducement Warrants issued in a private placement, and to approve the Reset of Exercise Price provision contained in the Inducement Warrants</div>

We are seeking stockholder approval, for
the issuance of up to 12,400,000 (subject to beneficial ownership limitations) shares of Common Stock issuable upon exercise of the Inducement
Warrants (defined below) and for approval of the Reset of Exercise Price provision found in Section 3(i) of the Inducement Warrants.

The information set forth in this Proposal
2 is qualified in its entirety by reference to the full text of Inducement Warrant (as defined below) and inducement offer (as defined
below) attached as exhibits 4.1 and 1013, respectively, to our Current Report on Form 8-K filed with the SEC on March 17, 2025.

Stockholders are urged to carefully read
these documents.

Background

On March 16, 2025, we entered into an inducement
offer to exercise existing Class A and Class B Warrants (the “Agreement”) with a certain accredited and institutional holder
(the “Holder”) of the Company’s Class A and Class B Warrants issued on May 17, 2024 (the “Existing Warrants”.
Pursuant to the Inducement Agreement, the Holder, upon exercise, received a new unregistered Common Stock Purchase Warrant (“Inducement
Warrants”) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), to purchase
up to a number of shares equal to 200% of the number of Warrant Shared issued pursuant to the exercise of Existing Warrants pursuant to
the Agreement (the “Inducement Warrant Shares”), which Inducement Warrants shall have an exercise price equal to $0.3736,
subject to adjustment as provided in the Inducement Warrant, will be exercisable any time after six